Compass utilizes social media for rare disease

Share this article:
BioMarin Pharmaceuticals has tasked Compass Healthcare with the redesign of its unbranded Phenylketonuria (PKU) community website, www.PKU.com. The new site is slated to launch during Q2 2009.

In order to reach the roughly 12,000 individuals diagnosed with PKU in the US, Compass hopes to foster online engagement within the PKU community. The new site will allow registered members to maintain blogs and create other content. Static content created by BioMarin is subject to review by a panel of community members, according to Kristin Keller, VP, client services, at Compass. The site will also offer recipes and a diet food wiki, notes Keller. 

PKU is a genetic condition that prohibits the body from metabolizing phenylalanine (Phe), an amino acid. 
PKU sufferers must avoid foods high in protein. 

“The purpose of the PKU.com site is to provide the PKU community with support and resources to better manage their disease,” said Keller. 

BioMarin markets Kuvan, a prescription treatment that lowers Phe levels in the bloodstream.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.